- Home /
- About Us
ABOUT
SEQIRUS
Seqirus is a leader in the fight against influenza with an innovative portfolio of influenza products. With over a century's worth of commitment to influenza combined with robust, global manufacturing capabilities, Seqirus is a go-to partner for you.
Expertise Through Experience
-
1916: Founded on Quality
The Commonwealth Serum Laboratories — now known as CSL Limited — is founded in Australia, with renowned bacteriologist Dr. William Penfold serving as the first director. His founding principle: the organization will “live or die by the quality of its products.”4
-
1916: Founded on Quality
The Commonwealth Serum Laboratories — now known as CSL Limited — is founded in Australia, with renowned bacteriologist Dr. William Penfold serving as the first director. His founding principle: the organization will “live or die by the quality of its products.”4
-
1918-1919: Fighting Spanish Influenza
After causing millions of deaths around the world, the Spanish influenza pandemic strikes Australia. CSL rapidly produces 3 million doses of a mixed bacterial vaccine, later shown to have effectively combatted the complications of the disease.4
-
1933: Breakthrough in Influenza Understanding
Scientists at the National Institute for Medical Research in London discover viruses cause influenza — not bacteria.4
-
1944: Fighting the Influenza Virus
CSL begins production on egg-based influenza vaccines in order to supply one million doses to Australian and British troops. The egg-based method of production is developed from the pioneering work of Macfarlane Burnet, a scientist at the Walter and Eliza Hall Institute of Medical Research.4
-
1951: Global Influenza Network
The World Health Organization designates CSL as an Influenza Reference Laboratory, recognizing its technical capabilities and the importance of the Southern Hemisphere in observing the ever-changing influenza virus.4
-
1957-1958: Asian Influenza Pandemic
CSL responds quickly to protect Australians from the Asian influenza pandemic, producing 1.6 million doses of pandemic vaccine.4
-
1968-1969: Hong Kong Influenza Pandemic
CSL produces 5 million doses of a pandemic vaccine for Australians to fight against the emerging Hong Kong influenza pandemic. Following the pandemic, CSL uses new resources to invest in its production process and improve its seasonal influenza vaccine.4
-
1973: Technical Expertise in Influenza
CSL begins to adapt (re-assort) influenza strains to grow better in eggs, providing the resulting “manufacturing seeds” to the WHO each season. The WHO then shares the seeds with all manufacturers worldwide for vaccine production.4
-
1978: Fighting More Strains of Influenza
CSL transitions its seasonal influenza vaccine from bivalent (2 strain) to trivalent (3 strain).4
-
1992: WHO Influenza Designation
CSL becomes a WHO Influenza Collaborating Centre, strengthening the organization’s role in the global influenza network.4
-
1994: International Expansion
CSL acquires a United States-based cell culture company, JRH Biosciences, beginning expansion to the United States and Europe.4
-
2009: H1N1 Response
As the H1N1 influenza pandemic accelerates, CSL's rapid response equips Australia to deliver influenza vaccines quickly to its vulnerable population — one of the first countries in the world to do so.2,3
Introducing Cell Culture Influenza Vaccines
As part of pandemic preparedness plans, Novartis Influenza Vaccines, later acquired by CSL, and the United States government announce the construction of a state-of-the-art manufacturing facility where the first approved cell-culture influenza vaccine would be produced.4 -
2012: Business Reorganization in Australia
CSL creates bioCSL, a stand-alone business unit dedicated to vaccines, pharmaceuticals, and diagnostics.4
-
2015: Becoming Seqirus
CSL acquires and combines the Novartis Influenza Vaccine business with bioCSL to form Seqirus, the second-largest Influenza Vaccine manufacturer in the world. Following the integration, Seqirus expands production capacity to better meet global demand.1
2015: Influenza Vaccine Innovations
Seqirus receives FDA approval for FLUAD® (Influenza Vaccine, Adjuvanted), the first adjuvanted seasonal influenza vaccine, which gives Seqirus a differentiating product in its portfolio. Seqirus also completes significant regulatory submissions for the approval of quadrivalent influenza vaccines.4,52015: Diversifying the Portfolio
CSL acquires the rights to commercialize RAPIVABTM (peramivir injection), an IV treatment for acute uncomplicated influenza.4 -
2016: An FDA-Approved Cell Culture-Derived Quadrivalent Influenza Vaccine
The FDA approves FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the first 4-strain, cell culture-derived, inactivated seasonal influenza vaccine.4,6
2016: A Century on the Front Line of Fighting Influenza
Seqirus is a leading manufacturer and supplier of influenza vaccines globally. Our global network includes manufacturing sites on 3 continents, research and development practices, and a commercial presence in 20 countries. Our 3,000+ employees are passionate, skilled experts who are driven to save as many lives as possible in the fight against influenza.2
Manufacturing at the Global Level
With extensive research and production expertise and manufacturing plants in the US, UK, Australia, and Germany, Seqirus is a major contributor to influenza prevention and control worldwide.2




Science and Innovation
Innovative technologies are vital to help fight the spread of influenza. At Seqirus, we're proud of our pioneering portfolio of vaccines, and our work to provide you with new and better solutions never stops. From our adjuvanted FLUAD® to our cell-based FLUCELVAX® QUADRIVALENT, we hope to transform the way influenza vaccine is developed and inspire confidence against seasonal influenza.
SEE OUR INNOVATIONReferences
- CSL. 100 years and just getting started. https://www.csl.com/en-us/our-company/our-story/celebrating-100-years. Accessed October 25, 2018.
- About us. Seqirus website. https://www.seqirus.com/about. Accessed October 25, 2018.
- US Department of Health and Human Services. First U.S. cell-based flu vaccine plant set for dedication facility's ability to produce cell-based pandemic flu vaccine marks historic change. https://www.phe.gov/Preparedness/new/Pages/cellflu-111212.aspx. Published December 12, 2011. Accessed September 28, 2018.
- CSL: 100 Years Timeline Booklet. 2016.
- Centers for Disease Control and Prevention. Flu vaccine with adjuvant, brand name FLUAD. https://www.cdc.gov/flu/protect/vaccine/adjuvant.htm. Updated October 18, 2018. Accessed October 25, 2018.
- Centers for Disease Control and Prevention. Cell-based flu vaccines. https://www.cdc.gov/flu/protect/vaccine/cell-based.htm. Updated October 4, 2018. Accessed October 25, 2018.
LEARN.
ORDER.
MANAGE.
By creating an account with us, you can see specific product
pricing, make a purchase, and manage your shipments easily.